- Home
- ARMP vs OCCI Comparison
ARMP vs OCCI Comparison
Compare ARMP & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- OCCI
- Stock Information
- Founded
- ARMP N/A
- OCCI N/A
- Country
- ARMP United States
- OCCI United States
- Employees
- ARMP N/A
- OCCI N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- ARMP Health Care
- OCCI Finance
- Exchange
- ARMP Nasdaq
- OCCI Nasdaq
- Market Cap
- ARMP 125.7M
- OCCI 135.3M
- IPO Year
- ARMP N/A
- OCCI N/A
- Fundamental
- Price
- ARMP $5.73
- OCCI $4.79
- Analyst Decision
- ARMP Strong Buy
- OCCI
- Analyst Count
- ARMP 1
- OCCI 0
- Target Price
- ARMP $9.00
- OCCI N/A
- AVG Volume (30 Days)
- ARMP 759.0K
- OCCI 115.8K
- Earning Date
- ARMP 11-07-2025
- OCCI 12-11-2023
- Dividend Yield
- ARMP N/A
- OCCI 24.32%
- EPS Growth
- ARMP N/A
- OCCI N/A
- EPS
- ARMP N/A
- OCCI N/A
- Revenue
- ARMP $6,868,000.00
- OCCI N/A
- Revenue This Year
- ARMP $8.43
- OCCI N/A
- Revenue Next Year
- ARMP N/A
- OCCI $10.19
- P/E Ratio
- ARMP N/A
- OCCI N/A
- Revenue Growth
- ARMP 84.67
- OCCI N/A
- 52 Week Low
- ARMP $0.90
- OCCI $5.47
- 52 Week High
- ARMP $16.34
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- ARMP 63.43
- OCCI 40.59
- Support Level
- ARMP $4.65
- OCCI $4.55
- Resistance Level
- ARMP $6.36
- OCCI $4.88
- Average True Range (ATR)
- ARMP 1.34
- OCCI 0.16
- MACD
- ARMP 0.01
- OCCI 0.02
- Stochastic Oscillator
- ARMP 22.25
- OCCI 56.82
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.